ArticleDiscover oncology2026
Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signatures.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low-Dose Cytarabine Plus G-CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study.Cancer medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances, over half of AML patients relapse or become refractory to chemotherapy. TREM1 (CD354), a regulator of tumor inflammation and immune evasion in solid cancers, remains poorly characterized in AML, especially in underrepresented populations like Egyptians. We aimed to evaluate TREM1 expression in de novo AML, its association with high-risk features (FLT3-ITD, CD123), and its prognostic impact on treatment response and survival.
methodsIn this prospective case-control study, TREM1 expression was quantified via flow cytometry (APC-conjugated anti-CD354) in 50 newly diagnosed AML patients and 50 matched controls. Patients were risk-stratified per ELN 2022 guidelines and treated with standard induction chemotherapy. TREM1 levels (CD45dim/SSC-low blasts) were correlated with molecular markers (FLT3-ITD, NPM1, cytogenetics), immunophenotypic profiles (CD2/CD7/CD19/CD56/CD123), and clinical outcomes (remission, survival). Statistical analyses included ROC-derived thresholds, Kaplan-Meier survival, and multivariate regression (SPSS v20.0).
resultsKey findings revealed significant TREM1 overexpression in AML blasts (median 21% [IQR: 12.8-43%]) compared to controls (15% [13-18%]; p = 0.01). Elevated TREM1 expression (> 21%) robustly predicted adverse prognosis (70% sensitivity, 75% specificity; AUC = 0.70, p = 0.04), chemotherapy resistance (non-complete remission: 77.8% sensitivity, 87% specificity; AUC = 0.80, p < 0.001), and inferior overall survival (median 5.5 vs. 11 months for low TREM1; p = 0.02). Notably, TREM1 expression correlated strongly with FLT3-ITD mutations (45.9% vs. 12.1% in wild-type; p = 0.01) and CD123 positivity (r = 0.29, p = 0.03), and was enriched in MLL-rearranged and complex karyotype subgroups (p = 0.04). Time-dependent ROC analysis confirmed sustained predictive accuracy (6-month AUC = 0.81), while TREM1/FLT3-ITD co-expression conferred a 5.4-fold mortality risk (p = 0.008). Subgroup analyses revealed consistent prognostic value across ELN risk categories.
conclusionsThese results establish TREM1 as a biomarker of high-risk AML characterized by FLT3/CD123 co-expression, intrinsic chemotherapy resistance, and poor survival. The prognostic utility of TREM1 (cutoff > 21%) may enhance risk stratification, while its immunomodulatory function underscores its potential as a therapeutic target. Future studies should validate these findings in larger, multiethnic cohorts and explore the mechanistic links between TREM1 and AML pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.